Initial anticoagulant treatment of pulmonary embolism: how can we better predict bleeding in the early days rather than the early months?
L Bertoletti - Chest, 2021 - journal.chestnet.org
Pulmonary embolism (PE) is the most severe clinical presentation of venous
thromboembolic disease (VTE). 1 Anticoagulant treatment is the cornerstone of its …
thromboembolic disease (VTE). 1 Anticoagulant treatment is the cornerstone of its …
Long term use of anticoagulant therapy for patients with pulmonary embolism
C Becattini, LA Cimini - Expert Review of Hematology, 2020 - Taylor & Francis
Introduction Anticoagulant treatment reduces recurrent venous thromboembolism (VTE) by
about 90% after index pulmonary embolism. Whether anticoagulant treatment also reduces …
about 90% after index pulmonary embolism. Whether anticoagulant treatment also reduces …
Evaluation of VTE-BLEED for predicting intracranial or fatal bleeding in stable anticoagulated patients with venous thromboembolism
Current international guidelines recommend discontinuing anticoagulant therapy for
unprovoked acute pulmonary embolism or deep vein thrombosis after the first 3 months of …
unprovoked acute pulmonary embolism or deep vein thrombosis after the first 3 months of …
[HTML][HTML] Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH
T Baglin, K Bauer, J Douketis, H Buller… - Journal of Thrombosis …, 2012 - jthjournal.org
This document gives guidance on deciding the duration of anticoagulation after a first
episode of an unprovoked pulmonary embolus (PE) and/or deep vein thrombosis (DVT) …
episode of an unprovoked pulmonary embolus (PE) and/or deep vein thrombosis (DVT) …
Comment on “Severity of pulmonary embolism at initial diagnosis and long-term clinical outcomes: From the COMMAND VTE Registry”
S Marin-Romero… - International …, 2021 - internationaljournalofcardiology.com
We read with great interest the paper by Yamashita and colleagues, in which they show that
patients with high-risk pulmonary embolism (PE) at initial diagnosis more frequently …
patients with high-risk pulmonary embolism (PE) at initial diagnosis more frequently …
Initial anticoagulation therapy with direct oral anticoagulants in patients with intermediate-high-risk pulmonary embolism: from the COMMAND VTE Registry-2
R Shigeno, K Kim, R Chatani, K Kaneda… - European Heart …, 2023 - academic.oup.com
Background Patients with intermediate-high-risk pulmonary embolism (PE) who have both
right ventricular dysfunction and elevated cardiac biomarkers are at a high risk of early …
right ventricular dysfunction and elevated cardiac biomarkers are at a high risk of early …
Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial
Background Current guidelines recommend a risk-adjusted treatment strategy for the
management of acute pulmonary embolism. This is a particular patient category for whom …
management of acute pulmonary embolism. This is a particular patient category for whom …
Optimal length of oral anticoagulant treatment for maximum benefit within 5 years after discontinuation of oral anticoagulants in patients with acute pulmonary …
Y Zhao, Y Luo, Y Cheng, H Wang… - BMJ Open …, 2023 - bmjopenrespres.bmj.com
Background Extended oral anticoagulant (OA) use is recommended in patients with acute
pulmonary embolism (PE) who require secondary thromboprophylaxis. Nevertheless, the …
pulmonary embolism (PE) who require secondary thromboprophylaxis. Nevertheless, the …
[HTML][HTML] Challenging pulmonary embolism-A new generation of oral anticoagulants
S Barra, L Paiva, R Providência - Journal of Thoracic Disease, 2012 - ncbi.nlm.nih.gov
Acute pulmonary embolism (PE) is a relatively common cardiovascular emergency, with an
estimated annual incidence of 70 cases per 100,000 individuals (1). Occlusion of the …
estimated annual incidence of 70 cases per 100,000 individuals (1). Occlusion of the …